Lung cancerA Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) - TRIDENT-3 - Zai Lab (Shanghai) Co., Ltd.
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer - BeiGene